Magnesium sulphate for women at term for neuroprotection of the fetus

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Nguyen, Thuy My N ^a   Crowther, Caroline A ^a   Wilkinson, Dominic ^a   Bain, Emily ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; PLACEBO; NEUROPROTECTIVE AGENT;

ADVERSE EVENT; APGAR SCORE; BIRTH; CESAREAN SECTION; CLUSTER ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FETUS; GESTATIONAL AGE; HOT FLUSH; HUMAN; NEUROPROTECTION; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; BRAIN INJURY; CEREBRAL PALSY; DRUG EFFECT; FEMALE; NEWBORN; PREGNANCY;

BRAIN INJURIES; CEREBRAL PALSY; FEMALE; FETUS; HUMANS; INFANT, NEWBORN; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENTS; PRE-ECLAMPSIA; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84875503115     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009395.pub2     Document Type: Review

References (47)

1. Witlin AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: A randomised, double-blind, placebo-controlled trial. American Journal of Obstetrics and Gynecology 1997;176(3):623-7.
2. Magann EF, Norman PF, Bass JD, Chauhan SO, Martin JN Jr, Morrison JC. Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline versus magnesium sulfate. International Journal of Obstetric Anesthesia 1995;4:140-4.
3. Blackwell S. Effects of intrapartum magnesium sulfate therapy on fetal adrenal function: a randomised placebo-controlled trial [abstract]. American Journal of Obstetrics and Gynecology 2001;184(1):s138.
4. Blackwell SC, Hallak M, Hassan SS, Berry SM, Russel E, Sorokin Y. The effects of intrapartum magnesium sulfate therapy on fetal serum interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha at delivery: a randomised, placebo-controlled trial. American Journal of Obstetrics and Gynecology 2001;184(7):1320-3.
5. Blackwell SC, Hallak M, Hassan SS, Norman G, Poole-Bryant K, Steffy B, et al.Clinical chorioamnionitis is associated with a decreased maternal-fetal concentration gradient of ionized magnesium in patients receiving magnesium sulphate: a randomised study. American Journal of Obstetrics and Gynecology 2000;182(1 Pt 2):S103.
6. Chen FP, Chang SD, Chu KK. Expectant management in severe preeclampsia: does magnesium sulfate prevent the development of eclampsia?. Acta Obstetricia et Gynecologica Scandinavica 1995;74:181-5.
7. Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. British Journal of Obstetrics and Gynaecology 1998;105:300-3.
8. Livingston JC, Livingston LW, Ramsey R, Mabie BC, Sibai BM. Magnesium sulfate in women with mild preeclampsia: a randomised controlled trial. Obstetrics & Gynecology 2003;101(2):217-20.
9. Magpie Trial Collaborative Group. Do women with preeclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:1877-90.
10. Moodley J, Moodley VV. Prophylactic anticonvulsant therapy in hypertensive crises of pregnancy - the need for a large randomized trial. Hypertension in Pregnancy 1994;13:245-52.
11. ACPR Group. Report of the Australian Cerebral Palsy Register, Birth Years 1993-2003. Cerebral Palsy Institute, Dec 2009.
12. Blair E, Watson L. Epidemiology of cerebral palsy. Seminars in Fetal and Neonatal Medicine 2006;11:117-25.
13. Bracci R, Buonocore G. Chorioamnionitis: a risk for fetal and neonatal morbidity. Biology of the Neonate 2003;83:85-96.
14. Canterino JC, Verma UL, Visintainer PF, Figueroa R, Klein SA, Tejani NA. Maternal magnesium sulfate and the development of neonatal periventricular leucomalacia and intraventricular hemorrhage. Obstetrics & Gynecology 1999;93:396-402.
15. Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks gestation: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology 2009;200:595-609.
16. Costantine MM, Drever M. Antenatal exposure to magnesium sulfate and neuroprotection in preterm infants. Obstetrics and Gynecology Clinics of North America 2011;38:351-66.
17. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD001060]
18. Crowther CA, Hiller JE, Doyle LW, Haslam RR, for the Australian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA 2003;290(20):2669-76.
19. Cruz M, Jenkins R, Silberberg D. The burden of brain disorders. Science 2006;312:53.
20. Dilenge ME, Majnemer A, Shevell MI. Long-term developmental outcome of asphyxiated term neonates. Journal of Child Neurology 2001;16:781-92.
21. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3]
22. Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2]
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
24. Finesmith RB, Roche K, Yellin PB, Walsh KK, Shen C, Zeglis M, et al.Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. American Journal of Perinatology 1997;14(5):303-7.
25. Gladstone M. A review of the incidence and prevalence, types and aetiology of childhood cerebral palsy in resource-poor settings. Annals of Tropical Paediatrics 2010;30(3):181-96.
26. Grether JK, Hoogstrate K, Walsh-Greene E, Nelson KB. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. American Journal of Obstetrics and Gynecology 1998;178(1 Pt 1):1-6.
27. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statisticis in Medicine 2006;25(20):3443-57.
28. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
29. Jacobsson B, Ahllin K, Hagberg G, Hagberg H, Gardosi J. Cerebral palsy and restricted growth status at birth: population-based case-control study. BJOG: an international journal of obstetrics and gynaecology 2008;115:1250-5. [DOI: 10.1111/j.1471-0528.2008.01827.x]
30. Jarvis S, Glinianaia SV, Blair E. Cerebral palsy and intrauterine growth. Clinics in Perinatology 2006;33:285-300.
31. Kimberlin DF, Hauth JC, Goldenberg RL, Bottoms SF, Iams JD, Mercer B, et al.The effect of maternal magnesium sulfate treatment on neonatal morbidity in < or = 1000-gram infants. American Journal of Perinatology 1998;15:635-41.
32. Lipsitz P. The clinical and biochemical effects of excess magnesium in the newborn. Pediatrics 1971;47:501-9.
33. MacLennan A. A template for defining a causal relation between acute intrapartum events and cerebral palsy: international consensus statement. BMJ 1999;319:1054-9.
34. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Leveque C, Hellor MF, et al.Magnesium sulfate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology 2007;114(3):310-8.
35. Marret S, Doyle LW, Crowther CA, Middleton P. Antenatal magnesium sulphate neuroprotection in the preterm infant. Seminars in Fetal and Neonatal Medicine 2007;12(4):311-7.
36. Maulik D, Mishra OP, Delivoria-Papadopoulos M. Effect of post-hypoxic MgSO(4) administration in utero on Ca(2+)-influx and Ca(2+)/calmodulin kinase IV activity in cortical neuronal nuclei. Neuroscience Letters 2005;386(2):127-32.
37. Menon R, Taylor RN, Fortunato SJ. Chorioamnionitis - a complex pathophysiologic syndrome. Placenta 2010;31(2):113-20.
38. Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, et al.Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology 2001;185(6 Suppl):S151.
39. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?. Pediatrics 1995;95:1-10.
40. The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child:National clinical practice guidelines. Adelaide: The University of Adelaide 2010.
41. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
42. Rouse D, Hirtz D, Thom E, Varner M, Alexander J, Spong C, et al.Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine 2008;359:895-905.
43. Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996;276(22):1805-10.
44. Magee L, Sawchuck D, Synnes A, von Dadelszen P, Magnesium Sulphate for Fetal Neuroprotection Consensus Committee. Society of Obstetricians and Gynaecologists of Canada Clinical Practice Guideline No. 258, May 2011. Magnesium sulphate for fetal neuroprotection. Journal of Obstetrics and Gynaecology Canada 2011;33(5):516-29.
45. Stanley F, Blair E, Alberman E. Cerebral Palsies: Epidemiology and Causal Pathways. Cambridge: Cambridge University Press, 2000.
46. Wu YW, Escobar GJ, Grether JK, Croen LA, Greene JD, Newman TB. Chorioamnionitis and cerebral palsy in term and near-term infants. JAMA 2003;290(20):2677-84.
47. Wu CS, Nohr EA, Bech BH, Vestergaard M, Catov JM, Olsen J. Health of children born to mothers who had preeclampsia: a population-based cohort study. American Journal of Obstetrics and Gynecology 2009;201(3):269-70.